Brokerages predict that AxoGen, Inc. (NASDAQ:AXGN) will announce earnings per share of ($0.09) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for AxoGen’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.11). AxoGen posted earnings per share of ($0.10) during the same quarter last year, which suggests a positive year over year growth rate of 10%. The business is scheduled to report its next earnings results on Wednesday, February 28th.
According to Zacks, analysts expect that AxoGen will report full-year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.30). For the next year, analysts forecast that the business will report earnings of ($0.27) per share, with EPS estimates ranging from ($0.32) to ($0.20). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.55 million. AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. AxoGen’s revenue for the quarter was up 43.2% compared to the same quarter last year.
Shares of AxoGen (NASDAQ:AXGN) traded up $0.70 during trading hours on Friday, reaching $28.10. 194,621 shares of the company were exchanged, compared to its average volume of 265,391. The company has a market capitalization of $958.04, a PE ratio of -70.25 and a beta of 0.40. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95. AxoGen has a fifty-two week low of $8.75 and a fifty-two week high of $31.70.
In other AxoGen news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $19.74, for a total transaction of $22,701,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jamie Mark Grooms sold 38,405 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,293,990 shares of company stock worth $26,494,898. Insiders own 9.33% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nationwide Fund Advisors grew its stake in shares of AxoGen by 5.5% during the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 774 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of AxoGen by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 23,616 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 1,335 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of AxoGen by 7.4% during the second quarter. Voya Investment Management LLC now owns 19,904 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 1,370 shares during the last quarter. Rhumbline Advisers grew its stake in shares of AxoGen by 11.4% during the second quarter. Rhumbline Advisers now owns 28,720 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 2,945 shares during the last quarter. Finally, Allianz Asset Management GmbH grew its stake in shares of AxoGen by 1.2% during the third quarter. Allianz Asset Management GmbH now owns 260,484 shares of the medical equipment provider’s stock worth $5,040,000 after buying an additional 2,979 shares during the last quarter. 66.00% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “AxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.09 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/21/axogen-inc-axgn-expected-to-post-earnings-of-0-09-per-share-2.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.